These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11126615)

  • 21. Search for technological reasons to develop a capsule or a tablet formulation with respect to wettability and dissolution.
    von Orelli J; Leuenberger H
    Int J Pharm; 2004 Dec; 287(1-2):135-45. PubMed ID: 15541920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.
    Volpato NM; Silva RL; Brito AP; Gonçalves JC; Vaisman M; Noël F
    Eur J Pharm Sci; 2004 Apr; 21(5):655-60. PubMed ID: 15066666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium.
    Savaşer A; Ozkan Y; Işimer A
    Farmaco; 2005 Feb; 60(2):171-7. PubMed ID: 15752476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on in vitro dissolution rate of geniposide in huangqin qingfei dispersible tablet].
    Cheng YJ; Zang C; Zhao XM; Feng QR
    Zhongguo Zhong Yao Za Zhi; 2003 Aug; 28(8):721-3. PubMed ID: 15015350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
    Bendas ER
    Arch Pharm Res; 2009 Sep; 32(9):1317-29. PubMed ID: 19784589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digoxin tablets--a review of the bioavailability problems.
    Sim SK
    Am J Hosp Pharm; 1976 Jan; 33(1):44-8. PubMed ID: 1266866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of nalidixic acid from uncoated tablets in humans--Part I: Correlation with the dissolution rates of the tablets.
    Ogata H; Aoyagi N; Kaniwa K; Shibazaki T; Ejima A; Takasugi N; Mafune E; Hayashi T; Suwa K
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):175-83. PubMed ID: 6715086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of ketoprofen bioavailability by formation of microsponge tablets.
    Comoglu T; Savaşer A; Ozkan Y; Gönül N; Baykara T
    Pharmazie; 2007 Jan; 62(1):51-4. PubMed ID: 17294814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a dissolution test for a once-a-day combination tablet of immediate-release cetirizine dihydrochloride and extended-release pseudoephedrine hydrochloride.
    Likar MD; Mansour HL; Harwood JW
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):543-51. PubMed ID: 15975755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on dissolution in vitro of Zhike Pingchuan sustained-release tablets].
    Li X; Feng Z; Huo W; Li Y; Wang B; Zhu S
    Zhongguo Zhong Yao Za Zhi; 2009 May; 34(10):1216-9. PubMed ID: 19673379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of microcalorimetry in determination of stability of enalapril maleate and enalapril maleate tablet formulations.
    Simoncic Z; Zupancic P; Roskar R; Gartner A; Kogej K; Kmetec V
    Int J Pharm; 2007 Sep; 342(1-2):145-51. PubMed ID: 17597314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative in vitro studies of allopurinol in commercial preparations].
    Georgarakis M; Iconomout N
    Pharmazie; 1984 Apr; 39(4):248-50. PubMed ID: 6739528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.
    Shoaib MH; Tazeen J; Merchant HA; Yousuf RI
    Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two dissolution apparatuses: rotating basket versus rotating flask.
    Koch HP; Alcorn G; Ritschel WA
    Pharmazie; 1983 Apr; 38(4):233-5. PubMed ID: 6867085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination and interpretation of in vitro solubility behavior of pharmaceutical agents. 2. The effect of surface tension of the dissolution medium on the liberation of drugs in commercial preparations (tablets, dragees)].
    Bornschein M; Eitz K; Voigt R
    Pharmazie; 1987 Feb; 42(2):83-6. PubMed ID: 3602064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [On the polymorphism of Barbiturates in powers and tablets. Part 5: The dissolution of recrystallized barbital substances and their release from tablet (author's transl)].
    Hollenbach K; Pintye-Hódi K; Kedvessy G
    Pharmazie; 1980 Feb; 35(2):95-8. PubMed ID: 7384189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative dissolution rate studies of commercial furosemide tablets.
    Gadalla MA; Ismail AA
    Pharmazie; 1981 Aug; 36(8):553-6. PubMed ID: 7291288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.